Firebrick Pharma Limited (FRE.AX)
AUD 0.08
(0.0%)
AUD 0.08
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -1.17 Million AUD | 82.71% |
| 2023 | -6.8 Million AUD | -79.18% |
| 2022 | -3.79 Million AUD | -55.65% |
| 2021 | -2.43 Million AUD | -62.77% |
| 2020 | -1.49 Million AUD | -106.61% |
| 2019 | -725.25 Thousand AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -1.17 Million AUD | 82.71% |
| 2024 Q4 | -138.72 Thousand AUD | 0.0% |
| 2024 Q1 | -449.2 Thousand AUD | 87.76% |
| 2024 Q2 | -898.41 Thousand AUD | -100.0% |
| 2024 Q3 | -138.72 Thousand AUD | 84.56% |
| 2023 Q1 | -1.56 Million AUD | 30.57% |
| 2023 FY | -6.8 Million AUD | -79.18% |
| 2023 Q4 | -3.67 Million AUD | -100.0% |
| 2023 Q3 | -1.83 Million AUD | 41.4% |
| 2023 Q2 | -3.13 Million AUD | -100.0% |
| 2022 Q4 | -2.25 Million AUD | -100.0% |
| 2022 FY | -3.79 Million AUD | -55.65% |
| 2022 Q3 | -1.12 Million AUD | 26.82% |
| 2022 Q2 | -1.54 Million AUD | -100.0% |
| 2022 Q1 | -770.5 Thousand AUD | 47.22% |
| 2021 Q1 | -489.63 Thousand AUD | 0.0% |
| 2021 FY | -2.43 Million AUD | -62.77% |
| 2021 Q4 | -1.45 Million AUD | -100.0% |
| 2021 Q3 | -729.88 Thousand AUD | 25.47% |
| 2021 Q2 | -979.27 Thousand AUD | -100.0% |
| 2020 FY | -1.49 Million AUD | -106.61% |
| 2019 FY | -725.25 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Mayne Pharma Group Limited | -174.23 Million AUD | 99.325% |